Russo Elena, Costantino Andrea, Veneroni Maria Vittoria, Festa Bianca Maria, Pellini Raul, Campo Flaminia, Petruzzi Gerardo, Spriano Giuseppe, Mercante Giuseppe, De Virgilio Armando
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Laryngoscope. 2023 Jun;133(6):1425-1433. doi: 10.1002/lary.30332. Epub 2022 Aug 4.
To determine the oncological outcomes of salvage transoral laser microsurgery (TLM) in the treatment of patients suffering from recurrent laryngeal cancer.
PubMed/MEDLINE, Cochrane Library, and Scopus databases were searched. English language, original studies investigating oncological outcomes of TLM in adult patients with recurrent laryngeal cancer were included. Data were pooled using a distribution-free approach for estimating summary local control (LC), disease-specific survival (DSS), and overall survival (OS) curves with random effects.
Two hundred and thirty-five patients underwent salvage TLM after primary (chemo)radiotherapy. The mean follow-up time was 60.8 months (95% CI: 32.7-88.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 74.2% (61.7-89.4), 53.9% (38.5-75.3), and 39.1% (25.2-60.8). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 88.4% (82.0-95.3), 67.8% (50.9-90.3), and 58.9% (42.7-81.1). Two hundred and seventy-one patients underwent TLM after primary laser treatment. The mean follow-up time was 70.9 months (95% CI: 36.9-104.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 72.2% (64.7-80.6), 53.2% (42.2-66.9), and 40.4% (29.6-55.2). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 92.1% (85.5-99.1), 77.0% (64.4-92.0), and 67.1% (51.6-87.3).
TLM is a valuable treatment option for the management of locally recurrent laryngeal carcinoma if performed by experienced surgeons and following rigorous patients' selection criteria. Further studies should be conducted to define stage-based clinical guidelines.
NA Laryngoscope, 133:1425-1433, 2023.
确定挽救性经口激光显微手术(TLM)治疗复发性喉癌患者的肿瘤学结局。
检索PubMed/MEDLINE、Cochrane图书馆和Scopus数据库。纳入英文的、调查TLM治疗成年复发性喉癌患者肿瘤学结局的原始研究。采用非参数方法汇总数据,以估计随机效应下的局部控制(LC)、疾病特异性生存(DSS)和总生存(OS)曲线。
235例患者在初次(化疗)放疗后接受了挽救性TLM。平均随访时间为60.8个月(95%CI:32.7 - 88.9)。1年、3年和5年的估计汇总LC率(95%CI)分别为74.2%(61.7 - 89.4)、53.9%(38.5 - 75.3)和39.1%(25.2 - 60.8)。1年、3年和5年的估计汇总DSS率(95%CI)分别为88.4%(82.0 - 95.3)、67.8%(50.9 - 90.3)和58.9%(42.7 - 81.1)。271例患者在初次激光治疗后接受了TLM。平均随访时间为70.9个月(95%CI:36.9 - 104.9)。1年、3年和5年的估计汇总LC率(95%CI)分别为72.2%(64.7 - 8I.6)、53.2%(42.2 - 66.9)和40.4%(29.6 - 55.2)。1年、3年和5年的估计汇总DSS率(95%CI)分别为92.1%(85.5 - 99.1)、77.0%(64.4 - 92.0)和67.1%(51.6 - 87.3)。
如果由经验丰富的外科医生进行,并遵循严格的患者选择标准,TLM是治疗局部复发性喉癌的一种有价值的治疗选择。应开展进一步研究以制定基于分期的临床指南。
NA《喉镜》,2023年,第133卷,第1425 - 1433页